Evidence map›Paper›PMID 27880792›Full record

ArticlePloS one2016

Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States.

Baiyu Yang, Fatma M Shebl, Lawrence R Sternberg, Andrew C Warner, David E Kleiner, Daniel C Edelman, Allison Gomez, Casey L Dagnall, Belynda D Hicks, Sean F Altekruse and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. The role of telomeres and telomerase in cirrhosis and liver cancer.Nature reviews. Gastroenterology & hepatology · 2019
    Review
  7. Article
  8. Article
  9. Telomere Length and Lung Cancer Mortality among Heavy Smokers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Baiyu YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Fatma M SheblYale University School of Public Health, New Haven, CT, 06520, United States of America.
Lawrence R SternbergPathology-Histotechnology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, United States of America.
Andrew C WarnerPathology-Histotechnology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, United States of America.
David E KleinerCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Daniel C EdelmanCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Allison GomezCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Casey L DagnallDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Belynda D HicksDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Sean F AltekruseDivision of Cancer Control & Population Sciences, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Brenda Y HernandezUniversity of Hawaii Cancer Center, Honolulu, HI, 96813, United States of America.
Charles F LynchUniversity of Iowa College of Public Health, Iowa City, IA, 52242, United States of America.
Paul S MeltzerCenter for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, United States of America.
Center for Cancer Research · USDivision of Cancer Epidemiology and GeneticsNational Cancer Institute · USFrederick National Laboratory for Cancer Research · USUniversity of Hawaii Cancer CenterUniversity of Iowa · USYale University · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
Cancer Genomics Technology DevelopmentZIABC011091 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MELTZER, PAUL S. · 2009 to 2025
$16.9M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA071789
6 · The paper itself

Abstract

backgroundTelomere shortening is an important molecular event in hepatocellular carcinoma (HCC) initiation; however, its role in HCC progression and prognosis is less clear. Our study aimed to examine the association of telomere length with survival of patients with HCC.

methodsWe measured telomere length in tumor and adjacent non-tumor tissues from 126 persons with HCC in the United States (U.S.) who were followed for mortality outcomes. Relative telomere length (RTL) was measured by a monochrome multiplex quantitative polymerase chain reaction assay. Multivariable Cox proportional hazards modeling was used to calculate hazard ratios (HRs) and 95% CIs for the association between telomere length and all-cause mortality. We also examined associations between telomere length and patient characteristics using multiple linear regression.

resultsDuring a mean follow-up of 6.0 years, 79 deaths occurred among 114 individuals for whom survival data were available. The ratio of RTL in tumor relative to non-tumor tissue was greater for individuals with regional or distant stage tumors (0.97) than localized stage tumors (0.77), and for individuals with grade III or IV tumors (0.95) than grade II (0.88) or grade I (0.67) tumors. An RTL ratio ≥1 was not associated with survival (HR 0.92, 95% CI 0.55, 1.55) compared to a ratio <1, after adjusting for age at diagnosis, sex, tumor stage and tumor size. Similarly, RTL in the tumor and non-tumor tissue, respectively, were not associated with survival.

conclusionsThis U.S. based study found that telomeres may be longer in more aggressive HCCs. There was no evidence, however, that telomere length was associated with survival of patients with HCC. Future investigations are warranted to clarify the role of telomere length in HCC prognosis.

Indexed as

AgedCarcinoma, HepatocellularDemographyFemaleHumansLiver NeoplasmsMaleMiddle AgedMultiplex Polymerase Chain ReactionNeoplasm GradingNeoplasm StagingProportional Hazards ModelsTelomereTelomere Shortening

Identifiers

PMID27880792
PMCPMC5120796
OpenAlexW2556817732

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.